Heparin-induced thrombocytopenia

Current Opinion in Critical Care

Volumn 21, Issue 6, 2015, Pages 576-585

  Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Disseminated intravascular coagulation; Heparin induced thrombocytopenia; Ischemic limb gangrene with pulses; Shock liver

Indexed keywords

BLOOD CLOTTING FACTOR 7; D DIMER; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; ANTICOAGULANT AGENT; THROMBOCYTE FACTOR 4;

ANTICOAGULANT THERAPY; CARDIOGENIC SHOCK; CLINICAL TRIAL (TOPIC); CRITICAL LIMB ISCHEMIA; CRITICALLY ILL PATIENT; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE; MICROTHROMBUS; PARTIAL THROMBOPLASTIN TIME; REVIEW; SEPTIC SHOCK; THROMBOCYTE TRANSFUSION; THROMBOSIS; CHEMICALLY INDUCED; COMPLICATION; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; IMMUNOLOGY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME FACTOR;

ANTICOAGULANTS; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; HEPARIN; HUMANS; PLATELET COUNT; PLATELET FACTOR 4; THROMBOCYTOPENIA; TIME FACTORS;

EID: 84947071610     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000259     Document Type: Review

References (89)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocyto-penia. Am J Med 1996; 101:502-507.
2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
3. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524.
4. Warkentin TE. HITlights: a career perspective on heparin-induced thrombo-cytopenia. Am J Hematol 2012; 87 (Suppl 1):S92-S99.
5. Warkentin TE. Agents for the treatment of heparin-induced thrombocytope-nia. Hematol/Oncol Clin N Am 2010; 24:755-775.
6. Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med 2015; 373:642-655.
7. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-induced IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 2:1246-1249.
8. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb Haemost 1992; 68:95-96.
9. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocyto-penia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71:247-251.
10. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506.
11. Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. CMAJ 2014; 186:929-933.
12. Padmanabhan A, Jones CG, Bougie DW, et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT patho-genesis. Blood 2015; 125:155-161.
13. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691-3699.
14. Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the patho-genesis of heparin-induced thrombocytopenia. Blood 2010; 116:5021-5031.
15. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 5th ed. Boca Raton, FL: CRC Press; 2013. pp. 24-76.
16. Greinacher A. Clinical practice heparin-induced thrombocytopenia. N Engl J Med 2015; 373:252-261.
17. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049-3051.
18. Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocyto-penia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003; 348:1067-1069.
19. Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015; 372:492-494.
20. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112:2607-2616.
21. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl):340S-380S.
22. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804-812.
23. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytope-nia. Arch Intern Med 2004; 164:66-70.
24. Linkins LA, Lee DH. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 5th ed. Boca Raton, FL: CRC Press; 2013. pp. 110-150.
25. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4:759-765.
26. Warkentin TE, Linkins LA. Nonnecrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost 2010; 8:1483-1485.
27. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120:4160-4167.
28. Warkentin TE, Cuker A. Differential diagnosis of heparin-induced thrombo-cytopenia and scoring systems. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 5th ed. Boca Raton, FL: CRC Press; 2013. pp. 77-109.
29. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pretest probability model for heparin-induced thrombocyto-penia based on broad expert opinion. J Thromb Haemost 2010; 8:2642-2650.
30. Warkentin TE, Chong BH, Greinacher A.Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1-7.
31. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 9 (Suppl 1):105-117.
32. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9:2498-2500.
33. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67:27-30.
34. Warkentin TE, Hayward CPM, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120:371-379.
35. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66:734-736.
36. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011; 2011:143-149.
37. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol 2015; 90:564-572.
38. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121:535-555.
39. Greinacher A, Warkentin TE. Acquired nonimmune thrombocytopenia. In: Marder VJ, Aird WC, Bennett JS, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 796-804.
40. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocy-topenia. N Engl J Med 2001; 344:1286-1292.
41. Warkentin TE, Sheppard JI, Moore JC, et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113:4963-4969.
42. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylac-toid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8:129-144.
43. Warkentin TE, Hirte HW, Anderson DR, et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97:489-491.
44. Hillis C, Warkentin TE, Taha K, Eikelboom JW. Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. Am J Hematol 2011; 86:603-606.
45. Warkentin TE, Sheppard JI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014; 123:2485-2493.
46. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94:132-135.
47. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006; 408-414.
48. Warkentin TE, Pai M, Cook RJ. Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. J Thromb Haemost 2012; 10:148-150.
49. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92:494-497.
50. Tassava T, Warkentin TE. Noninjection site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. Am J Hematol 2015; 90:747-750.
51. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011; 37:653-663.
52. Warkentin TE, Cook RJ, Sarode R, et al. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood 2015; 126:486-493.
53. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 2011; 27:805-823.
54. Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med 2012; 367:879-881.
55. Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Exp Opin Drug Saf 2014; 13:25-43.
56. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost 2015; 41:49-60.
57. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombo-cytopenia in postcardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 2010; 8:30-36.
58. Selleng S, Selleng K, Wollert HG, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopul-monary bypass. J Thromb Haemost 2007; 6:428-435.
59. Warkentin TE, Moore JC, Vogel S, et al. The serological profile of early-onset and persisting postcardiac surgery thrombocytopenia complicated by "true" heparin-induced thrombocytopenia. Thromb Haemost 2012; 107:998-1000.
60. Trehel-Tursis V, Louvain-Quintard V, Zarrouki Y, et al. Clinical and biological features of patients suspected or confirmed to have heparin-induced throm-bocytopenia in a cardiothoracic surgical ICU. Chest 2012; 142:837-844.
61. Warkentin TE. Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. Chest 2012; 142:815-816.
62. Selleng S, Selleng K, Friesecke S, et al. Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. J Thromb Thrombolysis 2015; 39:60-67.
63. Levine RL, Hergenroeder GW, Francis JL, et al. Heparin-platelet factor 4 antibodies in intensive care unit patients: an observational seroprevalence study. J Thromb Thrombolysis 2010; 30:142-148.
64. Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg 2011; 213:10-17.
65. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007; 82:1037-1043.
66. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6:1304-1312.
67. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710-2715.
68. Warkentin TE, Sheppard JI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108:2937-2941.
69. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010; 115:1797-1803.
70. Warkentin TE, Sheppard JI, Heels-Ansdell D, et al. Heparin-induced throm-bocytopenia in medical surgical critical illness. Chest 2013; 144:848-858.
71. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305-1314.
72. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99:2530-2536.
73. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128:837-884.
74. Douketis J, Cook DJ, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: the DIRECT study. Arch Intern Med 2008; 168:1805-1812.
75. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20:357-363.
76. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 2006; 4:894-896.
77. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl):e495S-e530S.
78. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced throm-bocytopenia: a report of four cases and review of the literature. Transfusion 2008; 48:2128-2132.
79. Refaai MA, Chuang C, Menegus M, et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1419-1421.
80. Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125:1470-1476.
81. Kelton JG, Hursting MJ, Heddle N, Lewis BE. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibitors. Blood Coagul Fibrinolysis 2008; 19:471-475.
82. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytope-nia: an overview. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 5th ed. Boca Raton, FL: CRC Press; 2013. pp. 315-355. http://www.hospira.com/en/images/EN-3339-tcm81-92293.pdf [Accessed 28 Sep 2015]
83. Smythe MA, Forsyth LL, Warkentin TE, et al. Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia following cardiac surgery despite "therapeutic" anticoagulation with argatroban: potential role for PTT and ACT confounding. J Thorac Cardiovasc Anesth 2014; Aug 25. [Epub ahead of print]
84. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
85. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856.
86. Smythe MA, Warkentin TE, Stephens JL, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 2002; 71:50-52.
87. Warkentin TE. Coumarin-induced skin necrosis and venous limb gangrene. In: Marder VJ, Aird WC, Bennett JS, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 1308-1317.
88. Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94:958-964.
89. Schindewolf M, Steindl J, Beyer-Westendorf J. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocy-topenia (HIT)-findings from the GerHIT multicentre registry study. Thromb Res 2014; 134:29-35.